GlassScriptPhysician profile
Kelsey Brennan
NPI 1114606399
$4,433.30
in general payments reported to CMS, 2019-2025
24 companies · $3,318 in 2025
The $3,318 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,116 · 2025: $3,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,428 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,428.30 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $719.60 | 2024-2025 | Opzelura, Opzelura |
| Abbvie INC. | $607.43 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $430.58 | 2024-2025 | Dupixent |
| Botanix Sb INC | $360.62 | 2025 | Sofdra |
| Pfizer INC. | $344.27 | 2024-2025 | |
| Janssen Biotech, INC. | $248.25 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $247.32 | 2025 | Aklief, Nemluvio |
| Leo Pharma INC. | $228.04 | 2024-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $172.86 | 2024-2025 | Zoryve |
| Genzyme Corporation | $140.76 | 2024-2025 | |
| Amgen INC. | $136.82 | 2024-2025 | Otezla, Otezla |
| Ucb, INC. | $119.58 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $118.63 | 2025 | |
| Verrica Pharmaceuticals INC. | $116.91 | 2024-2025 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $108.94 | 2025 | Sotyktu |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $82.31 | 2024 | Vtama |
| Lilly USA, LLC | $76.39 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Novartis Pharmaceuticals Corporation | $42.26 | 2024 | |
| Organon LLC | $32.42 | 2025 | |
| Cipher Pharmaceuticals US LLC | $24.10 | 2025 | Natroba, Spinosad |
| Biofrontera INC. | $22.09 | 2025 | Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.49 | 2025 | Cabtreo |
| Almirall LLC | $16.97 | 2024 | Klisyri |
| Journey Medical Corporation | $16.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.